Your diagnosis (Pathology) of Breast Cancer is called Triple Negative (IBC), Locally Advanced, Invasive Ductal Carcinoma or High Grade Infiltrating Ductal Carcinoma (Stage 3b or higher! You have NOT been told: that the clinical name of these cancers is Inflammatory Breast Cancer. The clinical name of IBC makes the aforementioned diagnosis extremely time sensitive.
IBC is designated as T4d in the American Joint Committee on Cancer (AJCC) Tumor
Because inflammatory breast cancer forms in layers, your doctor may not feel a distinct lump during a breast exam and a mammogram may not detect one either. In most cases, inflammatory breast cancer is diagnosed after you or your doctor can see or feel breast changes such as redness, swelling, warmth, or an orange-peel look to the skin. Inflammatory Breast Cancer is a clinical Diagnosis (meaning visual) not a pathology diagnosis.
Diagnosing Inflammatory Breast Cancer can be difficult since the cancer is not seen on mammograms, and mammograms are often painful and difficult for patients with a tender and swollen breast. A skin punch or needle core biopsy, dedicated breast MRI, and/or PET (Positron Emission Tomography) scan may assist in determining the cause of symptoms.
Family physicians are usually the entry point to the health care system and are well-positioned to assess inflammation of the breast and recognize the warning signs of underlying inflammatory breast cancer. They are also important members of the team that provides support for breast cancer patients during treatment, follow-up, and end-of-life care.
There is NO lump that can be felt during a physical examination or seen in a screening mammogram, this makes diagnosis harder than with other breast cancers. The symptoms of inflammatory breast cancer may be mistaken for those of mastitis, which is an infection of the breast, or another form of locally advanced breast cancer. Most IBC patients are young women. It often strikes very young to young women before the recommended age of 40.
Inflammatory Breast Cancer (IBC) is a relatively rare subtype of breast cancer, patients diagnosed with IBC faces many barriers throughout their diagnosis and treatment; anyone who has been through the experience will tell you the same thing. Because there is such limited education and knowledge about IBC, patients can suffer for weeks before they are accurately diagnosed – and, unfortunately, because IBC spreads so rapidly, they just don’t have any time to spare. According to the Inflammatory Breast Cancer International Consortium. Like other types of breast cancer, inflammatory breast cancer can occur in men.
If you've been diagnosed with inflammatory breast cancer, it's completely understandable if you're feeling overwhelmed. Keep in mind, though, that there are a variety of treatment options available for inflammatory breast cancer.
Mammography has made it possible to detect many breast cancers before they produce and signs or symptoms. HOWEVER, Inflammatory breast cancer produces symptoms, so in the case of this cancer. Due to the rapid spread of IBC, this breast cancer is sometimes found between routine mammogram exams.
To diagnose inflammatory breast cancer, your doctor will perform a biopsy. Biopsy is a surgical procedure that removes some of the suspicious breast tissue for examination under a microscope.
Because inflammatory breast cancer usually does not begin as a distinct lump, but instead as changes to the skin, a skin punch biopsy is often used to make the diagnosis. If your doctor can see a distinct lesion, he or she may perform an ultrasound-guided core needle biopsy. Ultrasound is an imaging method that places a sound-emitting device on the breast to obtain images of the tissues inside. Guided by the ultrasound, the doctor inserts a hollow needle into the breast to remove several cylinder-shaped samples of tissue from the area of suspicion.
If the biopsy shows that inflammatory breast cancer is present, your doctor will order additional tests to figure out how much of the breast tissue and lymph nodes are involved, and whether or not the other breast is affected. Breast MRI, or magnetic resonance imaging, is considered the most reliable test for gathering more information about inflammatory breast cancer
Once IBC is diagnosed, additional tests are used to determine whether the cancer has spread outside the breast to other organs, such as the lungs, bones, or liver. This is called staging. Tests that may be used include: Chest X-ray - CT scan (computerized tomography) of the chest, abdomen, and pelvis. Bone scan to look for spread (metastasis) to the bones and liver function tests. You may want to ask your doctor whether this test would be useful in your treatment planning.
Multiple-gated acquisition (MUGA) scans some, cancer treatments, such as certain chemotherapy drugs, can cause changes in heart function. Multiple-gated acquisition (MUGA) scans are used to evaluate and monitor changes in the function of the heart throughout a patient’s treatment. MUGA scans help determine if the heart is pumping blood properly and, ultimately, if needed to modify a patient’s treatment regime.
Another test is the positron emission tomography (PET), which is a nuclear imaging technique that creates detailed, computerized pictures of organs and tissues inside the body. A PET scan can be used to detect cancerous tissues and cells in the body that may not always be found through computed tomography (CT) or magnetic resonance imaging (MRI).
To help prevent delays in diagnosis and in choosing the best course of treatment, an international panel of experts published guidelines on how doctors can diagnose and stage inflammatory breast cancer correctly. Their recommendations are summarized below.
Minimum criteria for a diagnosis of inflammatory breast cancer include the following:
Even if imaging tests show suspicious for breast cancer, a definitive diagnosis requires a tissue sample or biopsy. A biopsy may be taken of a small area of the breast ( an incisional biopsy), or the entire abnormal area may be removed at the time of biopsy (excisional biopsy).
Biopsy allows the pathologist (a physician with special training in the diagnosis of diseases based on tissue samples) to determine if breast cancer is present, and if so, what type of breast cancer. Biopsy also provides a tissue sample for further tests that are done to determine the best type of treatment. The diagnosis of inflammatory breast cancer can be challenging.
Inflammatory Breast Cancer prognosis (outlook) is generally not as good as it is for most other types of breast cancer and is more likely to come back after treatment than most other types of breast cancer. Prognosis describes the likely course and outcome of a disease that is, the chance that a patient will recover or have a recurrence. IBC is more likely to have metastasized (spread to other areas of the body) at the time of diagnosis than non-IBC cases. As a result, the dismal 5-year survival rate for patients with IBC is only 25% to 50% has remained unchanged for more than 30 years -in stark contrast to the average survival rate for all breast cancer types of 75%, and for early-stage, non-IBC of 90%. The median survival time for patients diagnosed with IBC is only 37 months. According to Oncology Times.
Many factors can influence a patient’s prognosis, including the type and location of the cancer, the stage, the patient’s age and overall health, and the extent to which IBC responds to treatment. The prognosis, or likely outcome, for a patient diagnosed with cancer is often viewed that the cancer will be treated successfully and that the patient will recover completely. IBC usually develops quickly and spreads aggressively to other parts of the body, therefore women diagnosed with this disease, in general, do not survive as long as women diagnosed with other types of breast cancer according to statistics from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program. Statistics have proven with IBC the rate of recurrence is quite high so a careful watch by both the patient and the physician should have a planned strategy for follow-ups. Since there is no known cure, patients are never told they are cured, instead the term “no evidence of disease” (NED) is used.
Women coping with the fear of IBC coming back and the uncertainty about the future is the hardest and least expected part of finishing treatments. IBC has a high reoccurrence rate, so post-treatment monitoring by you, the patient, and your medical team is very important. Please keep in mind that no one can predict what will happen to a particular patient because each person's situation is unique. Patients are encouraged to talk to their doctors about their prognosis given their particular situation.
Any health-related information provided on the web of the Fighting 4 the Tatas Breast Cancer Organization is made available strictly for informational purposes. In no way does this information replace the knowledge, expertise, skills, or judgment of a doctor or other qualified health professional. Such information cannot be used for diagnosis or treatment purposes. You should consult a doctor or a qualified health professional in connection with any specific medical question or issue concerning your health. The hyperlinks which connect you to other Internet sites are provided solely for reference purposes and the Fighting 4 the Tatas Breast Cancer Organization assumes no responsibility as to their use or content.